OncologyAstraZeneca
AstraZeneca Presents Five-Year Data for Calquence in Chronic Lymphocytic Leukemia
BMI
Biotechnology Media Insights
Editorial Team · April 22, 2025
AstraZeneca shares five-year follow-up data from ASCEND trial showing sustained progression-free survival benefit of Calquence in relapsed/refractory CLL.
AstraZeneca today presented five-year follow-up data from the Phase 3 ASCEND trial evaluating Calquence (acalabrutinib) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The data showed that Calquence maintained a significant progression-free survival benefit over investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab at five years.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.